Abstracts tagged "malignancy and myositis"

Abstract Number: 1777 • 2013 ACR/ARHP Annual Meeting
Antibodies Against TIF1-Gamma In Cancer Associated Myositis May Precede Cancer Symptoms and Persist After Cancer Removal
Ingrid E. Lundberg¹, Lara Dani², Maryam Dastmalchi², Maria Angeles Martinez³, Moises Labrador-Horrillo⁴ and Albert Selva O'Callaghan⁴, ¹Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ³Sant Pau Hospital, Barcelona, Spain, ⁴Vall d'Hebron General Hospital, Barcelona, Spain
Background/Purpose: Antibodies against TIF1-gamma have been detected in patients with cancer associated myositis (CAM) but it is not known whether the antibodies precede the diagnosis…
Abstract Number: 229 • 2012 ACR/ARHP Annual Meeting
Clinical Differences Between Adult and Juvenile Dermatomyositis Associated with Anti-NXP2 Autoantibodies
Sarah Tansley¹, Zoe Betteridge¹, Harsha Gunawardena², Lucy R. Wedderburn³, Hector Chinoy⁴, Robert G. Cooper⁵, Jiri Vencovsky⁶, Lenka Plestilova⁷, Ingrid E. Lundberg⁸, Katalin Danko⁹, Melinda Vincze¹⁰, Neil McHugh¹¹, UK JDRG¹² and EuMyoNet¹³, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Rheumatology, North Bristol NHS Trust, Bristol, United Kingdom, ³Rheumatology Unit , Institute of Child Health, University College London (UCL), London, United Kingdom, ⁴Rheumatology, The University of Manchester, Manchester, United Kingdom, ⁵Rheumatic Diseaes Center, Salford Royal Foundation Trust, Salford, United Kingdom, ⁶Institute of Rheumatology, Prague, Czech Republic, ⁷Institute of Rheumatology, Prague 2, Czech Republic, ⁸Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁹University of Debrecen, University of Debrecen, Debrecan, Hungary, ¹⁰University of Debrecen, University of Debrecen, Debrecen, Hungary, Debrecan, Hungary, ¹¹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ¹²Institute of Child Health, London, United Kingdom, ¹³Rheumatology Unit, Stockholm, Sweden
Background/Purpose: Myositis specific antibodies (MSA) can divide dermatomyositis patients into distinct clinical subsets and help predict the risk of disease complications such as interstitial lung…
Abstract Number: 216 • 2012 ACR/ARHP Annual Meeting
Clinical and Serological Associations of Malignancy in Adult Patients with Polymyositis and Dermatomyositis
Yuji Hosono¹, Ran Nakashima¹, Yoshitaka Imura², Naoichiro Yukawa³, Hajime Yoshifuji¹, Motomu Hashimoto⁴, Koichiro Ohmura⁵, Takao Fujii⁶ and Tsuneyo Mimori¹, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ³Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁴The Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵Rheumatology & Clin Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁶Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are systemic connective tissue disorders, which are often associated with internal malignancy. Several studies have reported the association between…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].